Theranostics in neuroendocrine neoplasms


Endocrine Oncology Themed collection - Theranostics in neuroendocrine neoplasms


The discovery of somatostatin receptor-targeting radionuclides was instrumental to the field of theranostics in which a molecular target is used for both diagnostics and therapeutics. Radioligand therapy with 177Lu-DOTATATE for neuroendocrine neoplasms was the first theranostic drug to be registered by FDA and EMA. This has led to the development of molecular imaging and therapy with radionuclides for many other indications, particularly in oncology. Consequently, 177Lu-PSMA has now completed phase 3 and is poised to be registered for advanced prostate cancer. This and other promising radioligand therapies will open up new therapeutic options for patients with endocrine tumors. Given their historical relevance for the discovery of theranostics in neuroendocrine neoplasms and their overexpression of peptide hormones receptors, this is still much more to be gained for clinicians dealing with neuroendocrine neoplasms by improving indications and safety of 177Lu-DOTATATE, developing other somatostatin receptor-based radionuclides and testing other radionuclide targets.

This collection aims to explore a wide range of current aspects of Theranostics, from the recent research on the somatostatin receptor agonists to lessons learned from the NETTER-1 and VISION Randomised control trials.

If you are interested in contributing an original research article to this collection, please submit your article proposal to


Collection Editor


Dr J Hans Hofland
Erasmus Medical Center
Rotterdam, Netherlands